- Regeneron Pharmaceuticals press release ( NASDAQ: REGN ): Q3 Non-GAAP EPS of $11.14 beats by $1.52 .
- Revenue of $2.94B (-14.8% Y/Y) beats by $80M .
- Third quarter 2022 EYLEA U.S. net sales increased 11% versus third quarter 2021 to a record $1.63 billion
- Third quarter 2022 Dupixent global net sales(recorded by Sanofi) increased 40% to $2.33 billion versus third quarter 2021
- FY2022, the company now expects adjusted gross margin on net product sales of 92.5% to 93% from prior outlook of 92% to 93%.
For further details see:
Regeneron Pharmaceuticals Non-GAAP EPS of $11.14 beats by $1.52, revenue of $2.94B beats by $80M